FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Pierre Canal

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
D Balin-Gauthier; Jean-Pierre Delord; Marie-Jeanne Pillaire; Philippe Rochaix; J-S Hoffman; Roland Bugat; Christophe Cazaux; Pierre Canal; B C Allal
Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.
Jean-Pierre Delord; Frédéric Léger; Pierre Canal; Muriel Poublanc; Roland Bugat; Etienne Chatelut
Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation.
Diane Balin-Gauthier; Jean-Pierre Delord; Philippe Rochaix; Valérie Mallard; Fabienne Thomas; Isabelle Hennebelle; Roland Bugat; Pierre Canal; Cuider Allal
In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Pierre Canal (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: D Balin-Gauthier; Jean-Pierre Delord; Marie-Jeanne Pillaire; Philippe Rochaix; J-S Hoffman; Roland Bugat; Christophe Cazaux; Pierre Canal; B C Allal
Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.
British journal of cancer 2008;98(1):120-8.
2006: Jean-Pierre Delord; Frédéric Léger; Pierre Canal; Muriel Poublanc; Roland Bugat; Etienne Chatelut
Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation.
Cancer chemotherapy and pharmacology 2006;58(2):189-94.
2006: Diane Balin-Gauthier; Jean-Pierre Delord; Philippe Rochaix; Valérie Mallard; Fabienne Thomas; Isabelle Hennebelle; Roland Bugat; Pierre Canal; Cuider Allal
In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Cancer chemotherapy and pharmacology 2006;57(6):709-18.
2005: Jean-Pierre Delord; Cuider Allal; M Canal; Eliane Mery; Philippe Rochaix; Isabelle Hennebelle; Anne Pradines; Etienne Chatelut; Roland Bugat; Sylvie M Guichard; Pierre Canal
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(12):1889-97.
2005: Antje Hoppe; Sophie Séronie-Vivien; Fabienne Thomas; Jean-Pierre Delord; Laurence Malard; Pierre Canal; Etienne Chatelut
Serum cystatin C is a better marker of topotecan clearance than serum creatinine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(8):3038-44.
2005: Jean-Pierre Delord; Jean-Yves Pierga; Véronique Dieras; Frédérique Bertheault-Cvitkovic; Francois Turpin; François Lokiec; Isabelle Lochon; Etienne Chatelut; Pierre Canal; Rosine Guimbaud; D Mery-Mignard; X Cornen; Z Mouri; Roland Bugat
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
British journal of cancer 2005;92(5):820-6.
2004: Thierry Louat; Yvan Canitrot; Sandra Jousseaume; Caroline Baudouin; Pierre Canal; Guy Laurent; Dominique Lautier
Atypical protein kinase C stimulates nucleotide excision repair activity.
FEBS letters 2004;574(1-3):121-5.
2003: Catalin Mita; Etienne Chatelut; M Bekradda; Patrick Soulié; Pierre Canal; Jean-Louis Misset; Esteban Cvitkovic; Roland Bugat
Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1776-82.
2003: Etienne Chatelut; Jean-Pierre Delord; Pierre Canal
Toxicity patterns of cytotoxic drugs.
Investigational new drugs 2003;21(2):141-8.
2003: Marie-Christine Etienne; F Leger; Xavier Pivot; Etienne Chatelut; René-Jean Bensadoun; Emmanuel Guardiola; Nicole Renée; Nicolas Magné; Pierre Canal; Gérard Milano
Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(4):643-7.
2003: Jean-Pierre Delord; Amine Umlil; Rosine Guimbaud; Nicolas Grégoire; Thierry Lafont; Pierre Canal; Roland Bugat; Etienne Chatelut
Population pharmacokinetics of oxaliplatin.
Cancer chemotherapy and pharmacology 2003;51(2):127-31.
2003: Stéphanie Arnould; Isabelle Hennebelle; Pierre Canal; Roland Bugat; Sylvie M Guichard
Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.
European journal of cancer (Oxford, England : 1990) 2003;39(1):112-9.
2002: Stéphanie Arnould; Sylvie M Guichard; Isabelle Hennebelle; Georges Cassar; Roland Bugat; Pierre Canal
Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
Biochemical pharmacology 2002;64(8):1215-26.
2002: A Lebugle; A Rodrigues; P Bonnevialle; J J Voigt; Pierre Canal; F Rodriguez
Study of implantable calcium phosphate systems for the slow release of methotrexate.
Biomaterials 2002;23(16):3517-22.
2002: Elisabeth Rouits; Sylvie M Guichard; Pierre Canal; Etienne Chatelut
Non-linear pharmacokinetics of irinotecan in mice.
Anti-cancer drugs 2002;13(6):631-5.
2002: Ashraf Montazeri; Stéphane Culine; Brigitte Laguerre; Frédéric Pinguet; François Lokiec; Nicolas Albin; Alain Goupil; Régine Déporte-Féty; Roland Bugat; Pierre Canal; Etienne Chatelut
Individual adaptive dosing of topotecan in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(2):394-9.
2002: Frédéric Léger; Sophie Séronie-Vivien; J Makdessi; Isabelle Lochon; Jean-Pierre Delord; C Sarda; Pierre Canal; Etienne Chatelut
Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective study.
European journal of cancer (Oxford, England : 1990) 2002;38(1):52-6.
2001: Sylvie M Guichard; Ashraf Montazeri; Etienne Chatelut; Isabelle Hennebelle; Roland Bugat; Pierre Canal
Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(10):3222-8.
2001: Sylvie M Guichard; Stéphanie Arnould; Isabelle Hennebelle; Roland Bugat; Pierre Canal
Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
Anti-cancer drugs 2001;12(9):741-51.
2001: A Patoux; Nathalie Bleyzac; A V Boddy; François Doz; Hervé Rubie; Gérard Bastian; Pascal Maire; Pierre Canal; Etienne Chatelut
Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children.
European journal of clinical pharmacology 2001;57(4):297-303.
2001: Sylvie M Guichard; Pierre Canal
[New pharmacology techniques and methods in oncology].
Bulletin du cancer 2001;88(1):85-9.
2000: Eric Solary; L Mannone; D Moreau; Denis Caillot; René-Olivier Casasnovas; H Guy; Monique Grandjean; J E Wolf; F André; P Fenaux; Pierre Canal; Bruno Chauffert; A Wotawa; M Bayssas; Philippe Genne
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes.
Leukemia 2000;14(12):2085-94.
2000: C Terret; E Erdociain; Rosine Guimbaud; Michèle Boisdron-Celle; howard mcleod; R Féty-Deporte; Thierry Lafont; Erick Gamelin; Roland Bugat; Pierre Canal; Etienne Chatelut
Dose and time dependencies of 5-fluorouracil pharmacokinetics.
Clinical pharmacology and therapeutics 2000;68(3):270-9.
2000: Etienne Chatelut; Pierre Canal; Roland Bugat
[Pharmacokinetics and individual dose adjustment of carboplatin].
Bulletin du cancer 2000;87 Spec No():17-23.
2000: Isabelle Hennebelle; C Terret; Etienne Chatelut; Roland Bugat; Pierre Canal; Sylvie M Guichard
Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.
Anti-cancer drugs 2000;11(6):465-70.
2000: A Fournet; Veronique Gilard; Myriam Malet-Martino; Robert Martino; Pierre Canal; M De Forni
Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump.
Cancer chemotherapy and pharmacology 2000;46(6):501-6.
2000: Ashraf Montazeri; Maud Boucaud; François Lokiec; Frédéric Pinguet; Stéphane Culine; R Déporte-Féty; Nicolas Albin; B Laguerre; Alain Goupil; Roland Bugat; Pierre Canal; Etienne Chatelut
Population pharmacokinetics of topotecan: intraindividual variability in total drug.
Cancer chemotherapy and pharmacology 2000;46(5):375-81.
2000: Rosine Guimbaud; Sylvie M Guichard; C Dusseau; V Bertrand; T Aparicio; Isabelle Lochon; Etienne Chatelut; Daniel Couturier; Roland Bugat; Stanislas Chaussade; Pierre Canal
Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans.
Cancer chemotherapy and pharmacology 2000;45(6):477-82.
2000: Etienne Chatelut; Xavier Pivot; Josiane Otto; Christine Chevreau; Antoine Thyss; Nicole Renée; Gérard Milano; Pierre Canal
A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.
European journal of cancer (Oxford, England : 1990) 2000;36(2):264-9.
1999: N Siméon; E Chatelut; Pierre Canal; Michel Nertz; François Couderc
Anthracycline analysis by capillary electrophoresis. Application to the analysis of daunorubicine in Kaposi sarcoma tumor.
Journal of chromatography. A 1999;853(1-2):449-54.
1999: Laurence Gladieff; Etienne Chatelut; M H Gaspard; R Skaf; M de Forni; J Mihura; Pierre Canal; Roland Bugat
[Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
Bulletin du cancer 1999;86(7-8):673-7.
1999: Sylvie M Guichard; C Terret; Isabelle Hennebelle; Isabelle Lochon; P Chevreau; E Frétigny; Janick Selves; Etienne Chatelut; Roland Bugat; Pierre Canal
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
British journal of cancer 1999;80(3-4):364-70.
1999: Etienne Chatelut; Lionel Rostaing; Nicolas Grégoire; Jean-Louis Payen; A Pujol; Jacques Izopet; G Houin; Pierre Canal
A pharmacokinetic model for alpha interferon administered subcutaneously.
British journal of clinical pharmacology 1999;47(4):365-71.
1999: N Perdaems; N Caunes; Pierre Canal; Etienne Chatelut
Possible excretion of etoposide via the intestinal mucosa.
Cancer chemotherapy and pharmacology 1999;43(6):520-1.
1999: Brigitte Tranchand; C Amsellem; Etienne Chatelut; Gilles Freyer; Athanassios Iliadis; Blandine Ligneau; Véronique Trillet-Lenoir; Pierre Canal; Isabelle Lochon; Claude Ardiet
A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients.
Cancer chemotherapy and pharmacology 1999;43(4):316-22.
1999: Pierre Canal; L Gautié; Nicolas Grégoire; N Perdaems; Etienne Chatelut
[Anticancer drugs pharmacokinetics update].
Bulletin du cancer 1999;86(1):85-9.
1998: Guy G Chabot; J Robert; François Lokiec; Pierre Canal
[Irinotecan pharmacokinetics].
Bulletin du cancer 1998;Spec No():11-20.
1998: L Gautié; Pierre Canal; A Menguy; J F Latour; I Bénard; M Courbard; P Brunelle; Y Carpentier; Frédéric Pinguet; R Chevrier; M Doly; M Watelet; M Brière; P Viau; M Duban; O German; P Gosselin; P L de La Jarriage; C Bertrand; M Pommier; D Prebay
[Analysis of hematopoietic growth factor prescriptions in 19 french cancer centers].
Bulletin du cancer 1998;85(12):1043-8.
1998: Pierre Canal; Etienne Chatelut; Sylvie M Guichard
Practical treatment guide for dose individualisation in cancer chemotherapy.
Drugs 1998;56(6):1019-38.
1998: Lionel Rostaing; E Chatelut; Jean-Louis Payen; Jacques Izopet; C Thalamas; H Ton-That; Jean-Pierre Pascal; D Durand; Pierre Canal
Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications.
Journal of the American Society of Nephrology : JASN 1998;9(12):2344-8.
1998: N Perdaems; Jean-Marc Bachaud; P Rouzaud; M Murris-Espin; C Hermant; J Mihura; Isabelle Lochon; G Houin; Pierre Canal; Etienne Chatelut
Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.
European journal of clinical pharmacology 1998;54(9-10):677-83.
1998: L Martin; Etienne Chatelut; A Boneu; L Rostaing; C Roussilhes; O Caselles; Pierre Canal
Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients.
Bulletin du cancer 1998;85(7):631-6.
1998: C Joqueviel; Robert Martino; Veronique Gilard; Myriam Malet-Martino; Pierre Canal; U Niemeyer
Urinary excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear magnetic resonance spectroscopy.
Drug metabolism and disposition: the biological fate of chemicals 1998;26(5):418-28.
1998: Sylvie M Guichard; Isabelle Hennebelle; Roland Bugat; Pierre Canal
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
Biochemical pharmacology 1998;55(5):667-76.
1998: Bernard Monsarrat; E Chatelut; I Royer; P Alvinerie; J Dubois; A Dezeuse; H Roche; S Cros; M Wright; Pierre Canal
Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4.
Drug metabolism and disposition: the biological fate of chemicals 1998;26(3):229-33.
1998: Pierre Canal; E Gamelin; G Vassal; J Robert
Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy.
Pathology oncology research : POR 1998;4(3):171-8.
1998: François Doz; Saïk Urien; Etienne Chatelut; J Michon; Hervé Rubie; J M Zucker; Pierre Canal; Gérard Bastian
A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children.
Cancer chemotherapy and pharmacology 1998;42(3):250-4.
1998: Sylvie M Guichard; Etienne Chatelut; Isabelle Lochon; Roland Bugat; Mondher Mahjoubi; Pierre Canal
Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice.
Cancer chemotherapy and pharmacology 1998;42(2):165-70.
1998: Marie-Christine Etienne; Etienne Chatelut; Xavier Pivot; M Lavit; A Pujol; Pierre Canal; Gérard Milano
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.
European journal of cancer (Oxford, England : 1990) 1998;34(1):92-7.
1998: L Nguyen; Etienne Chatelut; Christine Chevreau; Brigitte Tranchand; Isabelle Lochon; Jean-Marc Bachaud; A Pujol; G Houin; Roland Bugat; Pierre Canal
Population pharmacokinetics of total and unbound etoposide.
Cancer chemotherapy and pharmacology 1998;41(2):125-32.
1997: Sylvie M Guichard; D Cussac; Isabelle Hennebelle; Roland Bugat; Pierre Canal
Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.
International journal of cancer. Journal international du cancer 1997;73(5):729-34.
1997: Laurent P Rivory; MC Haaz; Pierre Canal; François Lokiec; J P Armand; Jacques Robert
Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(8):1261-6.
1997: S Bénézet; Etienne Chatelut; H Bagheri; F Rigal-Huguet; L Nguyen; J Pourrat; A Robert; Jean-Louis Montastruc; Pierre Canal
[Inefficacy of exchange-transfusion in case of a methotrexate poisoning].
Bulletin du cancer 1997;84(8):788-90.
1997: E Evene; Etienne Chatelut; Brigitte Tranchand; Pierre Canal; Isabelle Lochon; Athanassios Iliadis; Claude Ardiet
[Bayesian estimation of pharmacokinetic parameters of etoposide].
Bulletin du cancer 1997;84(7):699-703.
1997: S Bénézet; Rosine Guimbaud; Etienne Chatelut; Christine Chevreau; Roland Bugat; Pierre Canal
How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(6):607-9.
1997: Jean-Marc Bachaud; Etienne Chatelut; Pierre Canal; Nicolas Albin; Elie Yardeni; JM David; Elie Serrano; Nicolas Daly-Schveitzer
Radiotherapy with concomitant continuous cisplatin infusion for unresectable tumors of the upper aerodigestive tract: results of a phase I study.
American journal of clinical oncology 1997;20(1):1-5.
1997: Frédéric Pinguet; P Martel; Michel Fabbro; I Petit; Pierre Canal; Stéphane Culine; Cécile Astre; Françoise Bressolle
Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation.
Anticancer research 1997;17(1B):605-11.
1997: M J Caliaro; P Vitaux; C Lafon; Isabelle Lochon; A Néhmé; Annie Valette; Pierre Canal; Roland Bugat; Suzanne Jozan
Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines.
British journal of cancer 1997;75(3):333-40.
1996: Pierre Canal; C Gay; A Dezeuze; Jean-Yves Douillard; Roland Bugat; R Brunet; Antoine Adenis; P Herait; F Lokiec; A Mathieu-Boue
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(10):2688-95.
1996: Pierre Canal; E Chatelut
[Dose optimization in clinical oncology: pharmacokinetic-pharmacodynamic relationship].
Bulletin du cancer 1996;83(4):256-65.
1996: Etienne Chatelut; A V Boddy; B Peng; H Rubie; M Lavit; A Dezeuze; A D Pearson; Henri Roché; A Robert; D R Newell; Pierre Canal
Population pharmacokinetics of carboplatin in children.
Clinical pharmacology and therapeutics 1996;59(4):436-43.
1995: G Nouadje; H Rubie; E Chatelut; Pierre Canal; Michel Nertz; P Puig; François Couderc
Child cerebrospinal fluid analysis by capillary electrophoresis and laser-induced fluorescence detection.
Journal of chromatography. A 1995;717(1-2):293-8.
1995: Etienne Chatelut; A Dezeuze; M Lavit; Christine Chevreau; A Pujol; A Boneu; Henri Roché; G Houin; Roland Bugat; Pierre Canal
[Prediction of carboplatin clearance from morphological and biological patient characteristics].
Bulletin du cancer 1995;82(11):946-53.
1995: M Lavit; Christine Chevreau; Etienne Chatelut; V De Fenin; Isabelle Lochon; G Houin; Roland Bugat; Pierre Canal
[Relations between hematological toxicity and total and free plasma levels of etoposide in daily oral administration].
Bulletin du cancer 1995;82(8):660-4.
1995: A Nehmé; N Albin; M J Caliaro; Sylvie M Guichard; Suzanne Jozan; A M Julia; Roland Bugat; Pierre Canal
Mechanism of interaction between cisplatin and human recombinant interferon gamma in human ovarian-cancer cell lines.
International journal of cancer. Journal international du cancer 1995;61(5):643-8.
1995: Etienne Chatelut; Pierre Canal; V Brunner; Christine Chevreau; A Pujol; A Boneu; Henri Roché; G Houin; Roland Bugat
Prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Journal of the National Cancer Institute 1995;87(8):573-80.
1995: Etienne Chatelut; Christine Chevreau; V Brunner; M Martinez; G Houin; Roland Bugat; Pierre Canal
A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer.
Cancer chemotherapy and pharmacology 1995;35(5):391-6.
1995: V Brunner; P Houyau; Etienne Chatelut; Henri Roché; Pierre Canal
Cerebrospinal fluid concentrations of carboplatin in a patient without blood-brain barrier disruption.
Cancer chemotherapy and pharmacology 1995;35(4):352-3.
1995: F Lokiec; Pierre Canal; C Gay; Etienne Chatelut; Jean-Pierre Armand; Henri Roché; Roland Bugat; E Gonçalvès; A Mathieu-Boué
Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine.
Cancer chemotherapy and pharmacology 1995;36(1):79-82.
1994: L P Rivory; Etienne Chatelut; Pierre Canal; A Mathieu-Boué; J Robert
Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
Cancer research 1994;54(24):6330-3.
1994: A M Julia; Henri Roché; M Berlion; C Lucas; Gérard Milano; J Robert; J P Bizzari; Pierre Canal
Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.
British journal of cancer 1994;69(5):868-74.
1994: daniel schlaifer; M Attal; F Huguet; Pierre Canal; G Laurent; Jacques Pris
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.
Seminars in hematology 1994;31(2 Suppl 3):31.
1994: Jean-Marc Bachaud; N Albin; C Gay; Etienne Chatelut; M Benchalal; J M David; A Boneu; Elie Serrano; Pierre Canal; Nicolas Daly-Schveitzer
[Concomitant association of radiotherapy and chemotherapy (CDDP 4-6 mg/m2/daily in continuous i.v. administration) in locally advanced ORL tumors].
Bulletin du cancer 1994;81(3):212-8.
1994: Michel Attal; Pierre Canal; daniel schlaifer; Etienne Chatelut; A Dezeuze; F Huguet; C Payen; Jacques Pris; G Laurent
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(1):141-8.
1994: Etienne Chatelut; Lionel Rostaing; V Gualano; T Vissac; M De Forni; H Ton-That; J M Suc; Georges Houin; Pierre Canal
Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency.
Nephron 1994;66(2):157-61.
1994: A Nehme; A M Julia; Suzanne Jozan; C Chevreau; Roland Bugat; Pierre Canal
Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines.
European journal of cancer (Oxford, England : 1990) 1994;30A(4):520-5.
1993: Pierre Canal; M Attal; Etienne Chatelut; Sylvie M Guichard; F Huguet; C Muller; daniel schlaifer; G Laurent; Georges Houin; Roland Bugat
Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas.
Cancer research 1993;53(20):4850-4.
1993: P Houyau; C Gay; Etienne Chatelut; Pierre Canal; Henri Roché; Gérard Milano
Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
Journal of the National Cancer Institute 1993;85(19):1602-3.
1993: M Samadi-Baboli; Gilles FAVRE; Pierre Canal; G Soula
Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice.
British journal of cancer 1993;68(2):319-26.
1993: Henri Roché; A M Julia; Suzanne Jozan; C Muller; N Dastugue; M A Arquier; B Marques; G Laurent; Pierre Canal
Characterization and chemosensitivity of a human epithelioid sarcoma cell line (SARCCR 2).
International journal of cancer. Journal international du cancer 1993;54(4):663-8.
1993: M de Forni; V Gualano; Pierre Canal; P Martel; F Izar-Soum; Christine Chevreau; P Soulié; Henri Roché; Roland Bugat
[Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers].
Bulletin du cancer 1993;80(5):408-17.
1993: C Muller; Etienne Chatelut; V Gualano; M De Forni; F Huguet; M Attal; Pierre Canal; G Laurent
Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion.
Cancer chemotherapy and pharmacology 1993;32(5):379-84.
1992: M de Forni; Myriam Malet-Martino; P Jaillais; R E Shubinski; Jean-Marc Bachaud; L Lemaire; Pierre Canal; Christine Chevreau; Didier Carrié; P Soulié
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(11):1795-801.
1992: Marie-Thérèse Dimanche-Boitrel; H Pelletier; P Genne; J M Petit; C Le Grimellec; Pierre Canal; Claude Ardiet; Gérard Bastian; Bruno Chauffert
Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells.
International journal of cancer. Journal international du cancer 1992;50(5):677-82.
1992: Pierre Canal; J Robert; M Ramon; R Baurain; P Tresca; M de Forni; Michel Marty; E Pujade-Lauraine; Roland Bugat; A Magis
Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities.
Clinical pharmacology and therapeutics 1992;51(3):249-59.
1991: Etienne Chatelut; H Roche; Y Plusquellec; F Peyrille; J De Biasi; A Pujol; Pierre Canal; Georges Houin
Pharmacokinetic modeling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children.
Journal of pharmaceutical sciences 1991;80(8):730-4.
1991: Etienne Chatelut; M de Forni; Pierre Canal; Christine Chevreau; H Roche; Y Plusquellec; N P Johnson; Georges Houin; Roland Bugat
Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(3):217-21.
1991: A M Julia; Pierre Canal; D Berg; Jean-Marc Bachaud; N J Daly; Roland Bugat
Concomitant evaluation of efficiency, acute and delayed toxicities of combined treatment of radiation and CDDP on an in vivo model.
International journal of radiation oncology, biology, physics 1991;20(2):347-50.
1991: A M Julia; Jean-Marc Bachaud; Pierre Canal; N J Daly
Radiosensitivity of jejunal mucosa after whole abdomen irradiation and CDDP pretreatment.
International journal of radiation oncology, biology, physics 1991;20(2):343-5.
1991: Pierre Canal; A Sqall; M de Forni; Christine Chevreau; A Pujol; Roland Bugat; H Roche; J Oustrin; Georges Houin
Chronopharmacokinetics of doxorubicin in patients with breast cancer.
European journal of clinical pharmacology 1991;40(3):287-91.
1991: M de Forni; S Lachau; F Huguet; Pierre Canal; G Laurent; Christine Chevreau; H Roche; Roland Bugat
Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases.
European journal of cancer (Oxford, England : 1990) 1991;27(6):735-9.
1990: L Bentouati; M S Baboli; H Hachem; M Hamza; Pierre Canal; G Soula
Hyperphosphatasemia related to three intestinal alkaline phosphatase isoforms: biochemical study.
Clinica chimica acta; international journal of clinical chemistry 1990;193(1-2):93-102.
1990: F Pinguet; Gilles FAVRE; Pierre Canal; J Tap; G Soula
[Injectable anti-cancer drugs. Stocking, preparation and administration].
Soins; la revue de référence infirmière 1990;(538-539):44-8.
1990: Gilles FAVRE; Pierre Canal; G Soula; J P Bagnoux; J C Jardillier
[Statement: alkaline phosphatases. Genetic aspects. Identification and clinical interpretation].
Annales de biologie clinique 1990;48(2):119-25.
1990: Etienne Chatelut; Christine Chevreau; E Blancy; A Lequellec; Pierre Canal; H Roche; G Houin; R Bugat
Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.
Cancer chemotherapy and pharmacology 1990;26(5):365-8.
1989: Pierre Canal; Y Plusquellec; Etienne Chatelut; R Bugat; J De Biasi; Georges Houin
A pharmacokinetic model for intraperitoneal administration of drugs: application to teniposide in humans.
Journal of pharmaceutical sciences 1989;78(5):389-92.
1989: Pierre Canal; Roland Bugat; Etienne Chatelut; M C Pinel; G Houin; Y Plusquellec; M Carton
Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26).
European journal of cancer & clinical oncology 1989;25(5):815-20.
1989: F Laurent; Pierre Canal; G Soula
Pharmacokinetics of Ro 03-8799 in mice bearing melanosarcoma: comparison with tumors without melanin.
International journal of radiation oncology, biology, physics 1989;16(4):1101-3.
1989: F X Thierry; I Vernier; J M Dueymes; H Roche; Pierre Canal; F Meeus; J P Pourrat; J J Conté
Acute renal failure after high-dose methotrexate therapy. Role of hemodialysis and plasma exchange in methotrexate removal.
Nephron 1989;51(3):416-7.
1989: E Blancy; Pierre Canal; D Berg; R Bugat
Cytotoxic effects of teniposide combined with cis-diammine-dichloroplatinum (II) on the in vitro Lewis lung carcinoma model: influence of the treatment schedule.
Fundamental & clinical pharmacology 1989;3(4):363-70.
1989: J L Guerin; Pierre Canal; J Douchez; G Soula
[Prognostic value of prostatic acid phosphatase in stage B and C prostatic cancer. Apropos of 84 cases].
Bulletin du cancer 1989;76(10):1077-82.
1989: Etienne Chatelut; Pierre Canal; M De Forni; Christine Chevreau; Georges Houin; Roland Bugat
[Phase I trial and pharmacokinetics of VM 26 combined with cisplatin administered by the intraperitoneal route without mixing time].
Bulletin du cancer 1989;76(8):893-6.
1989: Pierre Canal; Etienne Chatelut; M De Forni; Christine Chevreau; N Johnson; Georges Houin; Roland Bugat
[Comparison of the pharmacokinetics of cisplatin administered by the intraperitoneal route in 2 dosages: 100 and 200 mg/m2].
Bulletin du cancer 1989;76(8):879-82.
1989: Pierre Canal; M de Forni; Etienne Chatelut; Christine Chevreau; N P Johnson; Georges Houin; Roland Bugat
Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfate.
Acta medica Austriaca 1989;16(3-4):84-6.
1988: F Laurent; P Benard; Pierre Canal; G Soula
Autoradiographic distribution of [14C]-labelled pimonidazole in rhabdomyosarcoma-bearing rats and pigmented mice.
Cancer chemotherapy and pharmacology 1988;22(4):308-15.
1987: M Hamza; Pierre Canal; R Bugat; G Soula; L Douste-Blazy
Uptake and binding of teniposide (VM26) in Krebs II ascites cells.
Biochemical pharmacology 1987;36(10):1599-603.
1987: Pierre Canal; H Roche; M Pasquier; R Bugat; D Berg; G Soula; M Carton
Pharmacokinetics of high-dose i.v. alizapride in prevention of cisplatin-induced emesis.
Fundamental & clinical pharmacology 1987;1(3):213-7.
1986: Pierre Canal; R Bugat; B Rokoszak; D Berg; G Soula; H Roche
Pharmacokinetics and efficacy of i.v. and i.p. VM26 chemotherapy in mice bearing Krebs II ascitic tumors.
European journal of cancer & clinical oncology 1986;22(7):765-71.
1986: Pierre Canal; C Michel; R Bugat; G Soula; M Carton
Quantification of teniposide in human serum by high-performance liquid chromatography with electrochemical detection.
Journal of chromatography 1986;375(2):451-6.
1986: H Hachem; Gilles FAVRE; G Raynal; G Blavy; Pierre Canal; G Soula
Serum apolipoproteins A-I, A-II and B in hepatic metastases. Comparison with other liver diseases: hepatomas and cirrhosis.
Journal of clinical chemistry and clinical biochemistry. Zeitschrift für klinische Chemie und klinische Biochemie 1986;24(3):161-6.
1986: G Akel; P Benard; Pierre Canal; G Soula
Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography.
Cancer chemotherapy and pharmacology 1986;17(2):121-6.
1985: H Hachem; G Raynal; M Hamza; Pierre Canal; G Soula
Automated immunoturbidimetric assay of serum apolipoprotein A-II using the Cobas-Bio centrifugal analyser: influence of hyperlipoproteinemia.
Clinical biochemistry 1985;18(6):332-7.
1985: G Akel; Pierre Canal; G Soula
Renal elimination of the hypoxic cell radiosensitizer misonidazole in Wistar rats: influence of some drugs on its excretion.
European journal of drug metabolism and pharmacokinetics 1985;10(3):181-7.
1985: Pierre Canal; R Bugat; C Michel; H Roche; G Soula; P F Combes
Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma.
Cancer chemotherapy and pharmacology 1985;15(2):149-52.
1985: H Hachem; G Raynal; Gilles FAVRE; M Hamza; Pierre Canal; G Soula
[Determination of serum apolipoproteins A1 and B by immunoturbidimetry using the Cobas-Bio centrifugal analyzer. Influence of hyperlipemia].
Annales de biologie clinique 1985;43(6):885-90.
1985: F Laurent; G Akel; Pierre Canal; G Soula
[Effect of misonidazole (Ro 07-0582) and radiation on the monooxygenases of liver microsomes of the rat].
Journal de pharmacologie 1985;16(1):23-30.
1984: P Bellon; Pierre Canal; J Bernadou; G Soula
Use of electrochemical detection in the high-performance liquid chromatographic determination of hydroxylated ellipticine derivatives.
Journal of chromatography 1984;309(1):170-6.
1984: Pierre Canal; G Villeneuve; R Bugat; J P Armand; G Soula
[Plasma lactate dehydrogenase and its isoenzymes in nonseminomatous germ cell tumors of the testis].
Pathologie-biologie 1984;32(4):245-50.
1983: Pierre Canal; R Bugat; P Fernet; J Cassigneul; G Soula
Biological appraisal of liver status in adenocarcinomas.
Tumori 1983;69(6):509-14.
1983: G Akel; Pierre Canal; E Mockey; E Vandevoorde; F Laurent; G Soula
Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats.
Journal de pharmacologie 1983;14(1):67-77.
1982: Pierre Canal; G Soula
Comparative study of biochemical technique and radioimmunoassay for the measurement of serum prostatic acid phosphatase. Interest in the diagnosis of prostatic cancer?
Pathologie-biologie 1982;30(10):833-6.
1982: N Pradalier; Pierre Canal; A Pujol; Y Fregevu; G Soula
[Radioimmunoassay for prostatic acid phosphatase in human serum. Methodologic aspects (author's transl)].
Annales de biologie clinique 1982;40(1):45-50.
1981: G Akel; Pierre Canal; R Bugat; G Soula; P F Combes
[Plasma and tissues distribution of misonidazole (RO 07-0582) in the rat bearing a chimio induced tumor (author's transl)].
Journal de pharmacologie 1981;12(4):383-91.
1981: Pierre Canal; R Bugat; G Soula; P F Combes
[Determination of circulating ectopic beta HCG in solid tumors (author's transl)].
Pathologie-biologie 1981;29(3):150-4.
1980: Pierre Canal; R Bugat; G Soula; P F Combes
The measurement of total lactic dehydrogenase and its isoenzymes in solid tumours.
Biomedicine / [publiée pour l'A.A.I.C.I.G.] 1980;33(7):222-6.